Press release
Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020
NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will join Premas Biotech's Co-Founder and Managing Director Dr. Prabuddha Kundu in a webinar titled \"The Journey of Oral Insulin: Oramed Story\" on Wednesday October 28, 2020 at 9:00 am ET. Investors are invited to register for the webinar at: https://zoom.us/webinar/register/WN_63tKqgu9Rcq8ON2cwcKg_w?timezone_id=America%2FNew_York \n \n \nThroughout history, oral administration has been regarded as the most convenient mode of drug delivery, as it requires minimal expertise and invasiveness. Although oral delivery works well for small-molecule drugs, oral delivery of macromolecules (particularly proteins and peptides) has been limited by acidic conditions in the stomach and low permeability across the intestinal epithelium.\nOramed has made tremendous strides in the oral delivery of proteins and peptides, beginning with its oral insulin capsule ORMD-0801 which is entering pivotal Phase 3 trials in the U.S.\nOn Wednesday at 9 am ET, in the first part of a two-part webinar series, the session will focus on the journey of Oral Insulin - from concept to a successful Phase 3 candidate.\nAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.\nFor more information, please visit www.oramed.com.\nForward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential of ORMD-0801 to be the first commer...